Skip to main content

Table 3 Results of the multiple logistic regression models concerning the association between TZD exposure and 4 ADRs: Heart Failure, Myocardial Infarction, Edema and Hepatitis.

From: Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database

Heart failure

Odds ratio

(95% CI)

P

Age

1.04

(0.99 - 1.09)

0.0705

Obesity

5.69

(1.34 - 24.20)

0.0185

Thiazolidinediones

65.39

(17.678 - 241.93)

<0.0001

Hosmer and Lemeshow procedure

0.32

Myocardial infarction

   

Age

0.97

(0.95 - 1.00)

0.1076

Gender

1.73

(0.78 - 3.84)

0.1727

Thiazolidinediones

0.42

(0.05 - 3.17)

0.4039

Heart valve disorders

25.95

(2.63 - 255.47)

0.0053

Hypertension

0.34

(0.09 - 1.19)

0.0929

Hosmer and Lemeshow procedure

0.8254

Edema

   

Obesity

1.89

(0.58 - 6.17)

0.2863

Thiazolidinediones

25.09

(13.50 - 46.63)

<0.0001

Biguanides

0.42

(0.20 - 0.87)

0.02

Hosmer and Lemeshow procedure

0.8043

Hepatitis

   

Age

0.99

(0.97 - 1.00)

0.1167

Angina pectoris

0.43

(0.13 - 1.39)

0.1620

Cardiac arrhythmia

0.36

(0.08 - 1.52)

0.1686

Cardiac insufficiency

0.58

(0.25 - 1.37)

0.2217

Thiazolidinediones

0.84

(0.40 - 1.78)

0.6645

Non Steroidal Anti-Inflammatory Drugs

1.85

(1.13 - 3.01)

0.0134

Diuretics

0.58

(0.32 - 1.06)

0.0796

Calcium inhibitors

0.63

(0.32 -1.23)

0.1798

Angiotensin II inhibitors

0.68

(0.35 - 1.32)

0.2804

Hosmer and Lemeshow procedure

0.4397

  1. Potential confounding factors retained in the final model are indicated in the first column.